2017 Fiscal Year Final Research Report
Development of a new strategy for tumor immunity activation
| Project/Area Number |
16K15227
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
張替 秀郎 東北大学, 医学系研究科, 教授 (50302146)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 腫瘍免疫 / Tリンパ球 / Bach2 / 疲弊 |
|---|
| Outline of Final Research Achievements |
Cytotoxic T cells play critical roles in eliminating tumor cells with tumor-specific antigens. Although this tumor surveillance is effective during initial phases of tumorgenesis, it eventually fail to restrict tumor progression due to exhaustion of cytotoxic T cells. In addition, regulatory T cells and suppressor myeloid cells also inhibit the cytotoxic T cell activities. Based on our previous findings that the transcription factor Bach2 is essential for the differentiation of regulatory T cells, restricting cytotoxic T cell differentiation, this study was carried out to understand potential roles of Bach2 in the process of the T cell exhaustion and to develop a new strategy to activate tumor immunity. We found that Bach2-deficient T cells showed enhanced cytotoxic T cell differentiation and activity in vitro. Furthermore, many of the genes involved in T cell activation and cytotoxic activity were more highly expressed in Bach2-deficient T cells than in wild-type cells.
|
| Free Research Field |
医歯薬学
|
